CLINICAL TRIAL
    Trial No
    ClinicalTrials.gov ID
Principal Investigator
Coordinator
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
    SORENTO
    NCT05050942
     Recruiting
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Neuroendocrine tumors Dr. Petr Kavan

Aline Mamo
  514-340-8222 poste 5525